An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
NCT07153848 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2025-09-04
Summary
The goal of this observational study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects treated with lencanumab.
Conditions
- Alzheimer Disease
Sponsors & Collaborators
-
First Affiliated Hospital of Zhejiang University
lead OTHER
Eligibility
- Min Age
- 45 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2025-07-01
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Cognitive Neurology Unit Clinical Registry
NCT05925621 ·Status: RECRUITING
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Rivastigmine Mini-Tablet for Alzheimer's Disease
NCT06828289 ·Status: NOT_YET_RECRUITING
-
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
NCT06810960 ·Status: RECRUITING
-
Immunohistochemical Study of Neurodegenerative Diseases
NCT05518409 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
NCT06868030 ·Status: NOT_YET_RECRUITING
-
Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease
NCT03115814 ·Status: UNKNOWN
-
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
NCT01224106 ·Status: COMPLETED ·Phase: PHASE3
-
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
NCT06322667 ·Status: RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
NCT01767311 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of NH280105 in Healthy Adult Participants
NCT06870058 ·Status: COMPLETED ·Phase: PHASE1
-
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
NCT02488720 ·Status: COMPLETED
-
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
NCT04973189 ·Status: COMPLETED ·Phase: PHASE1
-
Feasibility of Lecanemab Registry and Clinical Outcome Measures
NCT06285448 ·Status: ENROLLING_BY_INVITATION
-
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
NCT02406027 ·Status: TERMINATED ·Phase: PHASE2
-
Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
NCT04804618 ·Status: RECRUITING
-
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT00731224 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
NCT00149175 ·Status: COMPLETED
-
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
NCT02051608 ·Status: COMPLETED ·Phase: PHASE3
-
The Mechanism of MicroRNAs Network in Alzheimer's Disease
NCT05055310 ·Status: COMPLETED
-
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
NCT01230853 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Pathway for Alzheimer's Disease in China (CPAD)
NCT01779310 ·Status: COMPLETED